What You Need To Know
The Centers for Disease Control and Prevention (CDC) has received five reports in the Vaccine Adverse Event Reporting System (VAERS) of hospitalizations for cardiac (e.g., atrial flutter) or neurologic (e.g., meningitis) events following vaccination with IXCHIQ (live attenuated chikungunya vaccine) among people 65 years of age and older. Many of the patients had significant underlying medical conditions.
CDC is reviewing the available information to investigate these cases further. More information will be released as it becomes available.
Health care providers are strongly encouraged to report to VAERS any clinically significant or unexpected events (even if you are not certain the vaccine caused the event) for any vaccine.
- Discuss the risks and benefits of IXCHIQ with your patients based on each traveler’s age, destination, trip duration, and planned activities.
- Review the latest CDC Travel Health Notices and be aware of countries and territories with outbreaks or evidence of chikungunya virus transmission among people within the last 5 years.
- Refer to the information in the Adverse Reactions section of the IXCHIQ package insert for additional safety information, including potential chikungunya-like adverse reactions.
- Report any adverse event following IXCHIQ vaccination to VAERS.